Vascular Cognitive and Motor Decline: Impact of aPL
血管认知和运动衰退:aPL 的影响
基本信息
- 批准号:8234526
- 负责人:
- 金额:$ 64.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-30 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAged, 80 and overAgingAntibodiesAntiphospholipid AntibodiesAutopsyBloodBlood - brain barrier anatomyBlood VesselsBlood specimenBrainC-reactive proteinCardiolipinsCell physiologyCerebrovascular DisordersCessation of lifeClinicalCognitionCognitiveCohort StudiesCommunitiesConsensusDataDiseaseElderlyEpidemiologic StudiesEpidemiologyFunctional disorderGlycoproteinsGoalsHealthHigh PrevalenceImpaired cognitionImpairmentInfarctionInflammationInternationalIschemic StrokeKnowledgeLinkLiteratureMagnetic Resonance ImagingMatrix MetalloproteinasesMeasuresMediatingMemoryMicroscopicMotorNeurologicNeurologic DysfunctionsNeuropsychological TestsOutcomePathologicPathway interactionsPerformancePermeabilityPersonsPrevalencePublic HealthResearch PersonnelRiskRoleSerineStrokeSystemic Lupus ErythematosusTestingTimeWomanaging populationcerebrovascularclinical practicecognitive functioncohortdisabilitydisorder controlfollow-upimprovedinflammatory markermenmortalitymotor impairmentnervous system disorderneuroimagingneuropathologytrendvascular factorwhite matter
项目摘要
DESCRIPTION (provided by applicant): Cerebrovascular disease is among the most common neurological diseases of aging and is increasing in prevalence with changing demographic trends. The two most common consequences of cerebrovascular disease are cognitive and motor decline, which are major contributors to poor health outcomes and mortality. Identifying associated factors, particularly ones for which treatments are available, is a priority for researchers in aging. Recent data suggest that antiphospholipid antibodies (aPL) increase in aging, and are present in about 35% of persons over the age of 80 years. While aPL increase risk of stroke by about two-fold, their relation to decline in cognitive and motor function, perhaps through an association with both clinical and subclinical cerebrovascular disease, is unclear. The proposed epidemiologic study will take advantage of a cohort of 1,100 community-dwelling women and men who are followed longitudinally with a high follow-up rate, and who come to autopsy with a high autopsy rate (R01AG17917), to test the hypotheses that aPL are related to cognitive and motor decline. The study will also examine the relation of aPL to cerebrovascular disease, including subclinical cerebrovascular disease assessed by complementary ante-mortem neuroimaging and postmortem neuropathology, and the extent to which aPL are related to cognitive and motor impairment after controlling for this disease. This would suggest the existence of neurobiologic mechanisms other than cerebrovascular disease linking aPL and cognitive and motor dysfunction. Finally, because factors with effects other than vascular may influence relations, the study will examine the role of makers of inflammation and altered blood-brain barrier permeability. The proposed study, relating aPL and other markers to cognitive and motor decline, and cerebrovascular disease in older, community-dwelling persons, will provide new knowledge regarding the role of aPL in common neurological conditions of aging. Because aPL are common vascular factors for which treatments are available, this study will provide new data which has the potential to improve public health by shifting current clinical practice paradigms and reducing the burden of neurological disease in aging.
PUBLIC HEALTH RELEVANCE: Cerebrovascular disease is increasing in prevalence with the aging population, and cognitive and motor decline, its' two most common consequences, are both major contributors to poor health outcomes and mortality. Identification of associated factors is priority for researchers in aging. These study relating blood vascular factors to cognitive and motor decline, and cerebrovascular disease, will fill a gap in knowledge in the field and has potential to provide data which will improve public health. an important
描述(由申请人提供):脑血管疾病是老年人最常见的神经系统疾病之一,随着人口统计学趋势的变化,其患病率正在增加。脑血管疾病的两个最常见的后果是认知和运动能力下降,这是导致不良健康结局和死亡率的主要因素。确定相关因素,特别是那些治疗方法,是研究人员在老龄化的优先事项。最近的数据表明,抗磷脂抗体(aPL)的增加,在老化,并存在于约35%的人超过80岁。虽然aPL使中风风险增加约两倍,但其与认知和运动功能下降的关系(可能通过与临床和亚临床脑血管疾病的相关性)尚不清楚。拟议的流行病学研究将利用一个由1,100名社区居住的女性和男性组成的队列,这些女性和男性接受了高随访率的纵向随访,并以高尸检率进行尸检(R01AG 17917),以检验aPL与认知和运动功能下降相关的假设。该研究还将研究aPL与脑血管疾病的关系,包括通过补充性生前神经成像和死后神经病理学评估的亚临床脑血管疾病,以及控制这种疾病后aPL与认知和运动障碍的相关程度。这表明存在脑血管疾病以外的神经生物学机制,将aPL与认知和运动功能障碍联系起来。最后,由于血管以外的其他因素可能会影响关系,该研究将检查炎症和改变血脑屏障通透性的制造商的作用。拟议中的研究,aPL和其他标志物的认知和运动能力下降,脑血管疾病的老年人,社区居民,将提供新的知识的作用,aPL在常见的神经系统疾病的老化。由于aPL是常见的血管因素,治疗是可用的,这项研究将提供新的数据,有可能通过改变目前的临床实践模式和减少衰老中神经系统疾病的负担来改善公共健康。
公共卫生相关性:随着人口老龄化,脑血管疾病的患病率正在增加,认知和运动能力下降是其两个最常见的后果,也是导致健康状况不佳和死亡的主要原因。识别相关因素是老龄化研究者的首要任务。这些研究将血管因素与认知和运动能力下降以及脑血管疾病联系起来,将填补该领域的知识空白,并有可能提供改善公众健康的数据。一个重要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zoe Arvanitakis其他文献
Zoe Arvanitakis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zoe Arvanitakis', 18)}}的其他基金
Brain cPLA2 as a mechanism for neuroinflammation in AD/ADRD with and without APOE4
大脑 cPLA2 作为 AD/ADRD 神经炎症的机制,有或没有 APOE4
- 批准号:
10464564 - 财政年份:2022
- 资助金额:
$ 64.85万 - 项目类别:
The role of blood and brain 5-hydroxymethylcytosine in linking vascular risk factors to ADRD in older White and Black persons
血液和脑 5-羟甲基胞嘧啶在老年白人和黑人血管危险因素与 ADRD 之间的联系中的作用
- 批准号:
10315659 - 财政年份:2021
- 资助金额:
$ 64.85万 - 项目类别:
Vascular Cognitive and Motor Decline: Impact of aPL
血管认知和运动衰退:aPL 的影响
- 批准号:
8336938 - 财政年份:2011
- 资助金额:
$ 64.85万 - 项目类别:
Vascular Cognitive and Motor Decline: Impact of aPL
血管认知和运动衰退:aPL 的影响
- 批准号:
8881036 - 财政年份:2011
- 资助金额:
$ 64.85万 - 项目类别:
Vascular Cognitive and Motor Decline: Impact of aPL
血管认知和运动衰退:aPL 的影响
- 批准号:
8728095 - 财政年份:2011
- 资助金额:
$ 64.85万 - 项目类别:
Vascular Cognitive and Motor Decline: Impact of aPL
血管认知和运动衰退:aPL 的影响
- 批准号:
8526334 - 财政年份:2011
- 资助金额:
$ 64.85万 - 项目类别:
Oxidative Stress, Aging and Alzheimer's Disease
氧化应激、衰老和阿尔茨海默病
- 批准号:
7556333 - 财政年份:2005
- 资助金额:
$ 64.85万 - 项目类别:
Oxidative Stress, Aging and Alzheimer's Disease
氧化应激、衰老和阿尔茨海默病
- 批准号:
7007680 - 财政年份:2005
- 资助金额:
$ 64.85万 - 项目类别:
Oxidative Stress, Aging and Alzheimer's Disease
氧化应激、衰老和阿尔茨海默病
- 批准号:
7367080 - 财政年份:2005
- 资助金额:
$ 64.85万 - 项目类别:
Oxidative Stress, Aging and Alzheimer's Disease
氧化应激、衰老和阿尔茨海默病
- 批准号:
6868496 - 财政年份:2005
- 资助金额:
$ 64.85万 - 项目类别: